EREG is a risk factor for the prognosis of patients with cervical cancer

• Published in: Frontiers in medicine Vol. 10; p. 1161835
• Main Authors: Li, Tianye, Feng, Ruijing, Chen, Bingxin, Zhou, Jianwei
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 20.03.2023
• Subjects: apoptosis; biomarker; cervical cancer; EREG; Medicine; prognosis prediction; proliferation; apoptosis; proliferation; biomarker; cervical cancer; prognosis prediction; EREG
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2023.1161835

Cervical cancer continues to threaten women's health worldwide. Identifying critical oncogenic molecules is important to drug development and prognosis prediction for patients with cervical cancer. Recent studies have demonstrated that epiregulin (EREG) is upregulated in various cancer types, which contributes to cancer progression by triggering the EGFR signaling pathway. However, the role of EREG is still unclear. In this study, we first conducted a comprehensive biological analysis to investigate the expression of EREG in cervical cancer. Then, we investigated the correlations between EREG expression level and clinicopathological features. In addition, we validated the effects of EREG expression on the proliferation and apoptosis of cervical cancer cells. Based on the public database, we found that the expression of EREG was higher in advanced cervical cancer samples. Survival analysis showed that EREG was a risk factor for the prognosis of cervical cancer. experiments demonstrated that EREG knockdown undermined proliferation and promoted apoptosis in cancer cells. EREG plays a vital role in the progression of cervical cancer, which contributes to hyperactive cell proliferation and decreased cell apoptosis. It might be a valuable target for prognosis prediction and drug development for cervical cancer in the future.